BMJ:气道护理对心脏骤停患者生存率的影响

2019-03-01 zhangfan MedSci原创

研究认为,对于院外心脏骤停患者,气道护理可提高无需除颤患者生存率,但对于需电击除颤患者生存率无显著影响

近日研究人员就院外心脏骤停患者气道护理(AAM)的效果进行了考察。

非住院心脏骤停患者参与研究,通过其首次心电图节律分成两个子队列需电击除颤组以及无需除颤组,研究的主要终点为1个月内生存率。

310620名患者参与研究,其中除颤组20516人,无除颤组290104人,分别有8459(41.2%)以及121890(42.0%)人在心肺复苏期间接受AAM。经时间依赖评分序贯匹配后,16114例除颤患者与236042例非除颤患者在同一分钟内配对。对于除颤组,AAM对患者生存率无显著影响(19.2 vs 18.6%,rr=1.00)。对于非除颤组,接受AAM患者的生存率提高(2.3 vs 1.8%,rr=1.27)。

研究认为,对于院外心脏骤停患者,气道护理可提高无需除颤患者生存率,但对于需电击除颤患者生存率无显著影响。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932648, encodeId=47a6193264879, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 04:27:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364299, encodeId=1dcc36429939, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Mon Apr 08 09:40:34 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848697, encodeId=56df184869ef7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Feb 10 11:27:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256695, encodeId=6964125669534, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Mar 03 04:27:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932648, encodeId=47a6193264879, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 04:27:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364299, encodeId=1dcc36429939, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Mon Apr 08 09:40:34 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848697, encodeId=56df184869ef7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Feb 10 11:27:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256695, encodeId=6964125669534, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Mar 03 04:27:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-04-08 gcwu82

    学习了谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1932648, encodeId=47a6193264879, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 04:27:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364299, encodeId=1dcc36429939, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Mon Apr 08 09:40:34 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848697, encodeId=56df184869ef7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Feb 10 11:27:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256695, encodeId=6964125669534, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Mar 03 04:27:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2020-02-10 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1932648, encodeId=47a6193264879, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 04:27:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364299, encodeId=1dcc36429939, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=650f104372, createdName=gcwu82, createdTime=Mon Apr 08 09:40:34 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848697, encodeId=56df184869ef7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Feb 10 11:27:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256695, encodeId=6964125669534, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Mar 03 04:27:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-03-03 guoyibin

相关资讯

2018 ERC复苏指南:心脏骤停抗心律失常药物的应用(更新版)

2018年11月,欧洲复苏委员会(ERC)更新了复苏指南中关于心脏骤停抗心律失常药物的应用建议,2018欧洲更新版复苏指南主要聚焦心脏骤停高级生命支持期间抗心律失常药物的作用。

欧洲复苏委员会复苏指南:2018更新-心脏骤停中的抗心律失常药物

摘要 此欧洲复苏委员会(ERC)复苏指南2018更新重点关注于抗心律失常药物在成人、儿童和婴儿心脏骤停、电除颤无效的难治性心室颤动/无脉性室性心动过速的高级生命支持中的应用。此更新发表于2018年国际复苏联络委员会(ILCOR)有关心肺复苏和心血管急救治疗推荐(CoSTR)国际共识发布之后。ILCOR CoSTR认为胺碘酮和利多卡因的获益是相似的。此ERC更新未对抗心律失常药物在电击无效的难

Crit Care Med:心脏骤停复苏后平均动脉血压升高与神经系统结局之间的关系

由此可见,心脏骤停复苏后最初6小时内血压升高与出院时良好的神经功能独立相关。需要进一步调查以确定针对平均动脉血压升高是否会改善心脏骤停后的神经系统结局。

Blood:危重儿童无症状中心静脉导管相关性血栓形成可不进行抗凝治疗

中心点:在189名儿童中,31位儿童存在无症状的中心静脉导管(CVC)相关性血栓,但尽管未进行治疗,仅一名儿童出现轻度的长期后遗症。紧急股动脉CVC置入术可预测2年内的残余血栓形成(p=0.02),并与急性加重和并发症相关。摘要:儿童无症状中心静脉导管(CVC)相关性血栓形成的发生率浮动在5-69%。对于无症状CVC相关性血栓形成导致的急性和长期并发症的发生率,如置管后血栓性综合征(PTS),尚无

揭开“心脏骤停”背后的真相,这个细节不能忽视!丨深度解析

41岁女性,既往体健,无高血压、糖尿病及冠心病史。3天前在餐后散步时,突发心悸,无胸闷、胸痛,后出现意识丧失,家人诉“呼吸停止,动脉搏动消失”,立即行心外按压,呼叫120,按压3分钟后,患者意识恢复。

Crit Care Med:停搏后治疗期间使用类固醇可能会改善心脏骤停幸存者结局

由此可见,在这项回顾性观察研究中,停搏后治疗期间使用类固醇可以提高出院和1年生存率。